Stable blood glucose plays a key role in diabetes care. A study in the Journal of Diabetes and Its Complications found that empagliflozin lowered glucose variability more effectively than metformin in drug-naïve adults with type 2 diabetes.

The randomized 12-week study included 46 drug-naïve adults with type 2 diabetes (HbA1c 6.5–10%). Participants received either empagliflozin 10 mg (n=23) or metformin 1000 mg (n=23) daily.
Empagliflozin reduced mean glucose variability by 19.6 mg/dL compared with 4.3 mg/dL for metformin. The HbA1c reduction was also greater with empagliflozin (−1.15%) than with metformin (−0.78%, p=0.049).

Both treatments increased time-in-range, but empagliflozin produced additional benefits, including greater weight loss, reduced waist circumference, higher HDL-cholesterol, and lower triglyceride and uric acid levels. Adverse events were mild and similar in both groups.

These findings show that empagliflozin not only lowers average glucose but also stabilizes daily fluctuations and improves metabolic parameters in early-stage type 2 diabetes.